Searched for
STRIDES PHARMA DEMERGER
Carlyle Group portfolio companies in advanced talks for a potential mergerSequent Scientific, which is in animal health business, posted revenue of around Rs 1,400 crore in FY24. It had earnings before interest, t...- OneSource in talks to raise Rs 1,670 crore in pre-listing roundOneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...
- Strides secures shareholders' nod for OneSource specialty CDMO unitStrides Pharma Science has received approval from shareholders and secured creditors to create OneSource, a specialty pharma CDMO. The comp...
- Proxy advisors vote against Strides Pharma’s consolidation schemeProxy advisory firms have recommended investors vote against Strides Pharma's proposal to consolidate businesses with Steriscience and Ones...
- Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profitStrides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. P...
- Reduce Strides Pharma Science, target price Rs 495: ICICI SecuritiesStrides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 4766.18 Crore) operating in Pha...
- Strides Pharma shares fall over 3% on plans to spin off CDMO, gelatin businessesAs per Trendlyne data, the average target price of Strides Pharma is Rs 530, which shows a downside of 2% from the current market prices. T...
- Strides Pharma to spin off CDMO assets to form a separate unitPharmaceutical company Strides Pharma is planning to demerge its contract development and manufacturing services (CDMO) assets into an asso...
- Strides Pharma announces business rejig. Shares end 7% up, hit 52 week highThe announcement was made by the company ahead of the market closing. The stock settled at Rs 536 on the NSE, up Rs 37, or 7% over Friday's...
- Strides Pharma to spin off contract development unitStrides Pharma Science on Monday said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin bus...
- Viatris buys Taparias' eyecare business for Rs 2,460 croreThe ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed f...
- After rallying 6 times in 3 years, this API maker just got first ‘sell’ ratingThe stock, which got listed at Rs 288 on June 27, 2018, hit a record high of Rs 1,859 on Wednesday, rising a solid 550 per cent, or 6.45 ti...
- Strides Pharma Q3 results: Net profit declines 62% to Rs 35 crThe company had posted a net profit of Rs 92.33 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a...
- 20 firms turned around in Q2! Are they compelling ‘buy’ ideas now?Seventeen of these 20 stocks posted up to 51 per cent YoY rise in net sales for the quarter.
- Beaten-down stocks that made a killing in the pre-poll rush of FIIsMarch quarter saw FPIs pump in Rs 46,939 crore into domestic equities.
- Can Glenmark Pharma taste success where its peers have not?Glenmark's current innovation pipeline consists of eight assets.
- D-Mart not an attractive proposition in long term: Deepak Shenoy, Capital Mind“There is a tremendous amount of value in auto ancillaries space.”
- Top stocks in focus on Friday, 1 September 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
- Strides Shasun Q3 net jumps over 3 fold; plans restructuringThe company had posted a net profit after taxes and minority interest and share of loss of associates and joint ventures of
- Strides eyes M&As for speciality pharma, R&DI-bankers, acting on behalf of Strides, have signalled M&A interest on part of the promoter group for its speciality pharma and R&D units.
Load More
